Drug Profile

Monalizumab - Innate Pharma

Alternative Names: Anti-NKG2A; IPH-22; IPH-2201; IPH-22XX; NN-8765; NNC 0141-0000-0100

Latest Information Update: 03 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novo Nordisk
Developer AstraZeneca; Innate Pharma; Istituto Clinico Humanitas; NCIC Clinical Trials Group; Netherlands Cancer Institute; Novo Nordisk
Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; NK cell lectin-like receptor subfamily C antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase III Non-small cell lung cancer
Phase II Acute myeloid leukaemia; Bladder cancer; HER2 positive breast cancer; Myelodysplastic syndromes; Small cell lung cancer; Squamous cell cancer
Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
No development reported Haematological malignancies
Discontinued Inflammation; Rheumatoid arthritis

02 Jun 2026 Efficacy and adverse events data from a phase II trial in Small cell lung cancer presented at the 62^nd Annual Meeting of the American Society of Clinical Oncology, 2026 (ASCO-2026)
29 Apr 2026 Hirva Mamdani re-initiates the Phase-II clinical trials in Small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in USA (IV) (NCT05903092)
31 Mar 2026 Assistance Publique withdrew a phase II MONAMI trial for Cancer (Combination therapy, Metastatic disease, Late-stage disease,Second-line therapy or greater) in France because the manufacturer can no longer supply the experimental treatment (IV)(NCT06152523)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com